MabThera (rituximab) 100 mg, 2 vials, Roche, Netherlands Order MabThera (rituximab) 100 mg, 2 vials, Roche, Netherlands. Medicine delivery from Europe within 4-5 days with storage conditions maintained. Payment on delivery. Contact +380996042415.
- Delivery of non-temperature-controlled medicines to Chisinau - $25.
Delivery of temperature-controlled medicines to Chisinau - $50.
Up to 5 packages can be sent per shipment. The price applies to one shipment. - Pickup from Odesafree
- Shipping within Ukraine by Nova Poshta at the carrier's rates.
Payment in UAH upon receipt of the order.
Delivery time
- Originator medicines: 5-7 days
- Generic medicines: 3-4 days
- Bank transfer to the settlement account after receiving the order
- Payment upon pickup in Odesa
Interchangeable drugs with the same active substance:
Mabthera
Reditux
Rituxim
Acellbia
Indications.
MabThera®is indicated for adults in the following cases:
non-Hodgkin's lymphoma
Monotherapy for patients with follicular lymphoma Stage III-IV, resistant to chemotherapy or are in the stage of second or subsequent relapses after chemotherapy.
Treatment of CD20-positive diffuse large B-cell non-Hodgkin lymphoma in combination with chemotherapy according to the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisolone).
Earlier treatment untreated follicular lymphoma stage III-IV in combination with chemotherapy.
Maintenance therapy of follicular lymphomas after receiving a response to induction therapy.
chronic lymphocytic leukemia
Treatment of previously untreated and recurrent / refractory chronic lymphocytic leukemia in combination with chemotherapy. There are only limited data regarding the effectiveness and safety of use in patients previously treated with monoclonal antibodies, including MabThera®, or in patients refractory to previous treatment with MabThera®plus chemotherapy.
rheumatoid arthritis
Treatment of severe rheumatoid arthritis (active form) in adults in combination with methotrexate when treatment with other disease-modifying antirheumatic drugs (DMARDs) is ineffective or intolerant, including treatment with one or more tumor necrosis factor inhibitors.
When used in combination with methotrexate Mabthera®reduces the rate of progression of destructive changes in joints according to X-ray data and improves physical function.
Granulomatosis with polyangiitis and microscopic polyangiitis
Treatment of severe forms of active granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis in combination with GCS to induce remission in adult patients
- Trade name:MabThera
- Chemical name:Rituximab
- Dosage:100 mg
- Quantity:2
- Dosage form:Vial
- Manufacturer:Roche, Germany
